D-1,2,4,5-tetra-O-benzyl-6-deoxy-myo-inositol-3-(dibenzyl)phosphate | 228412-19-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: D-1,2,4,5-tetra-O-benzyl-6-deoxy-myo-inositol-3-(dibenzyl)phosphate
• CAS: 228412-19-9
• 化学式: C₄₈H₄₉O₈P
• 分子量: 784.886
• InChiKey: MYRYWYLHCLPVAC-GAEWZJCOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.66
• 重原子数：
  57.0
• 可旋转键数：
  20.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.68
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  D-1,2,4,5-tetra-O-benzyl-6-deoxy-myo-inositol-3-(dibenzyl)phosphate 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 D-6-deoxy-myo-inositol-3-monophosphate
  参考文献：
  名称：

  Stereoselective synthesis of inositol mono, bis and trisphosphate analogues from 6-deoxy- d -inositol precursors

  摘要：

  The synthesis of opticaly pure deoxy-myo-inositol mono, bis and trisphosphate analogues is described from 4-O-benzyl-2,3-di-O-cyclohexylidene-6-deoxy-myo-inositol and corresponding 1,5 epimer chiro-inositol. These precursors, which derive from galactose, are used to accede to a variety of cyclitol intermediates employing protection/deprotection sequence. The phosphorylation procedure was performed to produce free and original substituted phosphate derivatives aimed to be incorporated through the lipidic cell membrane for in vivo evaluation. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00365-8
• 作为产物：
  描述：

  L-1,2,4-tri-O-benzyl-5,6-O-cyclohexylidene-3-deoxy-chiro-inositol 在 四氮唑 、 叔丁基过氧化氢 、 氢氧化钾 、 sodium tetrahydroborate 、 tetra-n-butylammonium per-ruthenate 、 甲基三辛基氯化铵 、 sodium carbonate 、 溶剂黄146 、 N-甲基吗啉氧化物 作用下， 以 乙醇 、 二氯甲烷 、 乙腈 为溶剂， 反应 8.25h， 生成 D-1,2,4,5-tetra-O-benzyl-6-deoxy-myo-inositol-3-(dibenzyl)phosphate
  参考文献：
  名称：

  Stereoselective synthesis of inositol mono, bis and trisphosphate analogues from 6-deoxy- d -inositol precursors

  摘要：

  The synthesis of opticaly pure deoxy-myo-inositol mono, bis and trisphosphate analogues is described from 4-O-benzyl-2,3-di-O-cyclohexylidene-6-deoxy-myo-inositol and corresponding 1,5 epimer chiro-inositol. These precursors, which derive from galactose, are used to accede to a variety of cyclitol intermediates employing protection/deprotection sequence. The phosphorylation procedure was performed to produce free and original substituted phosphate derivatives aimed to be incorporated through the lipidic cell membrane for in vivo evaluation. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00365-8